The Ministry of Food and Drug Safety (MFDS, Minister: Yu-Kyoung Oh) announced that it has approved Lilly Korea's new drug Omvoh Inj (mirikizumab-mrkz, recombinant) for the treatment of ulcerative colitis on the 7th.

Omvoh Inj. 20 mg/ml is a monoclonal antibody drug that binds to the p19 subunit of interleukin (IL)-23, providing a new therapeutic opportunity for patients with ulcerative colitis by inhibiting interleukin receptor downstream signaling that causes inflammatory responses.

Omvoh Inj. is indicated for the treatment of adult patients (aged 18 years or older) with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to,